These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 27146068)

  • 21. The use of onabotulinum toxin A (Botox(®)) in the treatment of chronic migraine at the Parma Headache Centre: a prospective observational study.
    Russo M; Manzoni GC; Taga A; Genovese A; Veronesi L; Pasquarella C; Sansebastiano GE; Torelli P
    Neurol Sci; 2016 Jul; 37(7):1127-31. PubMed ID: 27048312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety.
    Blumenfeld AM; Tepper SJ; Robbins LD; Manack Adams A; Buse DC; Orejudos A; D Silberstein S
    J Neurol Neurosurg Psychiatry; 2019 Mar; 90(3):353-360. PubMed ID: 30630956
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study.
    Stark C; Stark R; Limberg N; Rodrigues J; Cordato D; Schwartz R; Jukic R
    J Headache Pain; 2019 Jul; 20(1):81. PubMed ID: 31307383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of onabotulinumtoxinA treatment on efficacy, depression, anxiety, and disability in Turkish patients with chronic migraine.
    Demiryurek BE; Ertem DH; Tekin A; Ceylan M; Aras YG; Gungen BD
    Neurol Sci; 2016 Nov; 37(11):1779-1784. PubMed ID: 27418178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA.
    Torres-Ferrus M; Gallardo VJ; Alpuente A; Pozo-Rosich P
    J Headache Pain; 2020 Jul; 21(1):88. PubMed ID: 32652924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study.
    Young WB; Ivan Lopez J; Rothrock JF; Orejudos A; Manack Adams A; Lipton RB; Blumenfeld AM
    J Headache Pain; 2019 Jan; 20(1):10. PubMed ID: 30669961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis.
    Matharu M; Halker R; Pozo-Rosich P; DeGryse R; Manack Adams A; Aurora SK
    J Headache Pain; 2017 Dec; 18(1):78. PubMed ID: 28766236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term assessment of effectiveness and quality of life of OnabotulinumtoxinA injections in provoked vestibulodynia.
    Pelletier F; Girardin M; Humbert P; Puyraveau M; Aubin F; Parratte B
    J Eur Acad Dermatol Venereol; 2016 Jan; 30(1):106-11. PubMed ID: 26491951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine.
    Blumenfeld AM; Patel AT; Turner IM; Mullin KB; Manack Adams A; Rothrock JF
    J Prim Care Community Health; 2020; 11():2150132720959936. PubMed ID: 32985341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective real-world analysis of OnabotulinumtoxinA in chronic migraine post-National Institute for Health and Care Excellence UK technology appraisal.
    Andreou AP; Trimboli M; Al-Kaisy A; Murphy M; Palmisani S; Fenech C; Smith T; Lambru G
    Eur J Neurol; 2018 Aug; 25(8):1069-e83. PubMed ID: 29617060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. OnabotulinumtoxinA effectiveness on chronic migraine, negative emotional states and sleep quality: a single-center prospective cohort study.
    Aydinlar EI; Dikmen PY; Kosak S; Kocaman AS
    J Headache Pain; 2017 Dec; 18(1):23. PubMed ID: 28213829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe.
    Matharu M; Pascual J; Nilsson Remahl I; Straube A; Lum A; Davar G; Odom D; Bennett L; Proctor C; Gutierrez L; Andrews E; Johannes C
    Cephalalgia; 2017 Dec; 37(14):1384-1397. PubMed ID: 28758415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Botulinum toxin A in chronic refractory migraine: premarketing experience].
    Álvaro-González LC; Fernández-García JM; Aranzábal-Alustiza I; Castillo-Calvo B; Iriondo-Etxenagusia I; Rodríguez-Antigüedad A
    Rev Neurol; 2012 Oct; 55(7):385-91. PubMed ID: 23011856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative and Qualitative Pain Evaluation in Response to OnabotulinumtoxinA for Chronic Migraine: An Observational Real-Life Study.
    Altamura C; Brunelli N; Viticchi G; Salvemini S; Cecchi G; Marcosano M; Fofi L; Silvestrini M; Vernieri F
    Toxins (Basel); 2023 Apr; 15(4):. PubMed ID: 37104222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
    Silberstein SD; Blumenfeld AM; Cady RK; Turner IM; Lipton RB; Diener HC; Aurora SK; Sirimanne M; DeGryse RE; Turkel CC; Dodick DW
    J Neurol Sci; 2013 Aug; 331(1-2):48-56. PubMed ID: 23790235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of onabotulinumtoxinA for chronic migraine.
    Whitcup SM; Turkel CC; DeGryse RE; Brin MF
    Ann N Y Acad Sci; 2014 Nov; 1329():67-80. PubMed ID: 25399521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impulse control disorders in chronic migraine with medication overuse after onabotulinumtoxinA: A single-center prospective cohort study.
    d'Onofrio F; de Falco A; Costanzo A; Spitaleri D; Casucci G; Raimo S
    J Clin Neurosci; 2020 Oct; 80():152-155. PubMed ID: 33099338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. OnabotulinumtoxinA injections in chronic migraine, targeted to sites of pericranial myofascial pain: an observational, open label, real-life cohort study.
    Ranoux D; Martiné G; Espagne-Dubreuilh G; Amilhaud-Bordier M; Caire F; Magy L
    J Headache Pain; 2017 Dec; 18(1):75. PubMed ID: 28733943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment - real world outcomes.
    Talbot J; Stuckey R; Crawford L; Weatherby S; Mullin S
    J Headache Pain; 2021 Jan; 22(1):5. PubMed ID: 33421995
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.